Savara (SVRA) Fundamentals 2026 — Revenue Analysis | SniperIQ
Savara (SVRA) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Savara's market cap?
Savara (SVRA) has a market capitalization of approximately
What is Savara's P/E ratio?
Savara's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 8.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Savara?
Savara runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Savara pay a dividend?
Savara does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Savara financially healthy?
Savara carries a debt-to-equity ratio of 0.17x and a current ratio of 13.47x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Savara a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Savara (SVRA) the key facts are: market cap
Track Savara's full fundamentals live
Get Savara's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.